Cwm LLC Acquires 1,087 Shares of Organon & Co. (NYSE:OGN)

Cwm LLC raised its holdings in shares of Organon & Co. (NYSE:OGN) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,217 shares of the company’s stock after buying an additional 1,087 shares during the quarter. Cwm LLC’s holdings in Organon & Co. were worth $205,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Lindbrook Capital LLC raised its stake in Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock valued at $27,000 after purchasing an additional 1,428 shares during the last quarter. Harvest Fund Management Co. Ltd lifted its stake in shares of Organon & Co. by 495.5% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the period. Headlands Technologies LLC acquired a new stake in Organon & Co. during the third quarter worth about $35,000. EverSource Wealth Advisors LLC grew its position in Organon & Co. by 97.7% during the third quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock worth $39,000 after buying an additional 1,110 shares in the last quarter. Finally, Clear Street Markets LLC increased its stake in Organon & Co. by 588.9% during the third quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock valued at $40,000 after acquiring an additional 1,961 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Trading Up 0.6 %

NYSE OGN opened at $19.61 on Friday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08. The company has a market capitalization of $5.04 billion, a price-to-earnings ratio of 4.79, a PEG ratio of 0.92 and a beta of 0.81. The stock’s 50 day moving average is $18.19 and its two-hundred day moving average is $15.77.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.73 by $0.14. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. On average, analysts predict that Organon & Co. will post 4.1 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.71%. The ex-dividend date is Friday, May 10th. Organon & Co.’s payout ratio is 27.38%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on OGN. Piper Sandler lifted their price objective on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. The Goldman Sachs Group lifted their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday.

Insider Buying and Selling

In other news, insider Kirke Weaver purchased 2,720 shares of Organon & Co. stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the transaction, the insider now directly owns 15,181 shares in the company, valued at $278,723.16. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.17% of the stock is currently owned by corporate insiders.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.